Es werden neue Verbindungen der Formel (1) bereitgestellt, die aufgrund ihrer pharmazeutischen Wirksamkeit als PI3-Kinase Modulator zur Anwendung auf therapeutischem Gebiet zur Behandlung von entzündlichen oder allergischen Erkrankungen gelangen können. Beispielhaft seien hier entzündliche und allergische Atemwegserkrankungen, entzündliche Erkrankungen des Magen-Darm-Traktes und des Bewegungsapparates, entzündliche und allergische Hauterkrankungen, entzündliche Augenerkrankungen, Erkrankungen der Nasenschleimhaut, entzündliche oder allergische Krankheitszustände, bei denen Autoimmun-Reaktionen beteiligt sind oder Nierenentzündungen genannt.
Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection
作者:Wenhan Zhang、Shufeng Liu、Rayelle I. Maiga、Jerry Pelletier、Lauren E. Brown、Tony T. Wang、John A. Porco
DOI:10.1021/jacs.8b11477
日期:2019.1.23
rocaglate (flavagline) naturalproduct, aglaroxin C displays intriguing biological activity by inhibiting hepatitis C viral entry. To further elucidate structure-activity relationships and diversify the pyrimidinone scaffold, we report a concise synthesis of aglaroxin C utilizing a highly regioselective pyrimidinone condensation. We have prepared more than 40 aglaroxin C analogues utilizing various amidine
作为一种独特的 rocaglate (flavagline) 天然产物,aglaroxin C 通过抑制丙型肝炎病毒进入显示出有趣的生物活性。为了进一步阐明构效关系并使嘧啶酮支架多样化,我们报告了利用高度区域选择性嘧啶酮缩合的 aglaroxin C 的简明合成。我们已经利用各种脒缩合伙伴制备了 40 多种 aglaroxin C 类似物。通过对类似物的生物学评估,我们发现了两种先导化合物 CMLD012043 和 CMLD012044,它们显示出对丙型肝炎病毒进入抑制与翻译抑制的优先偏向。总体而言,该研究证明了化学合成能够产生具有靶向抑制偏向性和改善的治疗指数的天然产物变体。
[EN] PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3, 4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LA 5-FLUORO-1H-PYRAZOLO[3,4-B]PYRIDIN-3-AMINE ET DES DÉRIVÉS DE CELLE-CI
申请人:VERTEX PHARMA
公开号:WO2009018415A1
公开(公告)日:2009-02-05
The present invention relates to a process for the synthesis of 5-fluoro-1H-pyrazolo [3, 4-b]pyridin-3-amine in high yield and purity. The present invention also relates to processes for the synthesis of 5-fluoro-1H-pyrazolo [3, 4- b] ρyridin-3-amine derivatives. These processes are useful for preparing biologically active compounds, particularly certain GSK-3 inhibitors, or derivatives thereof. Reagents and conditi ons : i. Pd ( OAc )2, PPh3, Et3N, H2CO2; i i. 1 ) (COCl )2, CH2Cl2, cat. DMF; 2 ) NH3 (g ), dioxane, i i i. TFAA, Et3N, CH2Cl2, O°C; iv. H2NNH2. H2O, n-butanol, reflux.
The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.
The asymmetrichydrogenation of pyrimidines proceeded with high enantioselectivity (up to 99 % ee) using an iridium catalyst composed of [IrCl(cod)]2, a ferrocene‐containing chiral diphosphine ligand (Josiphos), iodine, and Yb(OTf)3 (cod=1,5‐cyclooctadiene). The chiral catalyst converted various 4‐substituted pyrimidines into chiral 1,4,5,6‐tetrahydropyrimidines in high yield. The lanthanide triflate